Published works

Chronic Kidney Disease (CKD)

Chronic Kidney Disease (CKD)

  • 137Urinary Level of Liver-Type Fatty Acid Binding Protein Reflects the Degree of Tubulointerstitial Damage in Polycystic Kidney Disease.Kidney Blood Press Res. 2018PubMed
  • 134Urinary liver-type fatty acid-binding protein levels as a potential risk factor for renal dysfunction in male HIV-infected Japanese patients receiving antiretroviral therapy: a pilot study.Int J STD AIDS. 2018PubMed
  • 130Urinary L-FABP level in children with nephrotic syndrome and tubular dysfunction.Pediatr Int.2018PubMed
  • 129Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucoselowering-independent manner.BMJ Open Diabetes Res Care.2017PubMed
  • 127Prediction of contrast induced acute kidney injury using novel biomarkers following contrast coronary angiography.QJM.2018PubMed
  • 126Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone- and salt-induced renal injury.Hypertens Res.2017PubMed
  • 125Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1a receptor expression.Eur J Pharmacol.2017PubMed
  • 124Urinary liver-type fatty acid-binding protein is associated with subendocardial viability ratio in middle- and older-aged adults.Clin Exp Hypertens.2017PubMed
  • 121Urine liver fatty acid binding protein and chronic kidney disease progression.Scand J Clin Lab Invest.2017PubMed
  • 120Urinary liver-type fatty acid binding protein is an independent predictor of stroke and mortality in individuals with type 1 diabetes.Diabetologia.2017 PubMed
  • 119Current Metabolic Status Affects Urinary Liver-Type Fatty-Acid Binding Protein in Normoalbuminuric Patients With Type 2 Diabetes.JClin Med Res.2017PubMed
  • 116Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia-reperfusion.Nephrology.2017PubMed
  • 113The association between urinary liver-type fatty acid-binding protein and chronic kidney disease classification in HIV-infected Japanese patients.Clin Exp Nephrol.2016PubMed
  • 111Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.FASEB J.2016PubMed
  • 107Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study.Cardiovasc Diabetol.15(1): 76, 2016.PubMed
  • 106Renoprotective effect of the xanthine oxidoreductase inhibitor, Topiroxostat,on Adenine-Induced Renal Injury.Am J Physiol Renal Physiol.310(11):F1366-1376, 2016.PubMed
  • 104Clinical utility of urinary liver-type fatty acid binding protein measured by latex-enhanced turbidimetric immunoassay in chronic kidney disease.Clin Chem Lab Med.2016.PubMed
  • 102Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD.Clin Exp Nephrol.20(2): 195-203, 2016.PubMed
  • 99Urinary markers in the early stage of nephropathy in patients with childhood-onset type 1 diabetes.Pediatr Nephrol.31(4):623-631, 2016.PubMed
  • 96Epoetin beta pegol alleviates oxidative stress and exacerbation of renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritis rats.Physiol Rep.3(12), 2015.PubMed
  • 95Urinary liver-type fatty acid-binding protein change in gestational diabetes mellitus.Diabetes Res Clin Pract.109(3): e36-e38, 2015.PubMed
  • 94Urinary Biomarkers and Risk of ESRD in the Atherosclerosis Risk in Communities Study.Clin J Am Soc Nephrol.10(11):1956-1963, 2015.PubMed
  • 91Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease.Scand J Clin Lab Invest.75(5): 421-427, 2015.PubMed
  • 89Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment? Nephrology.10(4):e0122212, 2015.PubMed
  • 88Distinct roles of urinary liver-type Fatty Acid-binding protein in non-diabetic patients with anemia.PLoS One.10(5): e0126990, 2015.PubMed
  • 87Circulating TNF Receptors 1 and 2 Are Associated with the Severity of Renal Interstitial Fibrosis in IgA Nephropathy.PLoS One.10(4): e0122212, 2015.PubMed
  • 85Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.Clin Exp Nephrol.19(6): 1044-1053, 2015.PubMed
  • 84Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus.Diabetologia.58(1): 188-198, 2015.PubMed
  • 81LDL-apheresis contributes to survival extension and renal function maintenance of severe diabetic nephropathy patients: a retrospective analysis.Diabetes Res Clin Pract.106(2): 241-246, 2014.PubMed
  • 80NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction.Clin Chem Lab Med.52(4): 537-546, 2014.PubMed
  • 74Urinary biomarkers of kidney injury are associated with all-cause mortality in the Women’s Interagency HIV Study (WIHS).HIV Med.15(5): 291-300, 2014.PubMed
  • 72Level of urinary liver-type fatty acid-binding protein is associated with cardiac markers and electrocardiographic abnormalities in type-2 diabetes with chronic kidney disease stage G1 and G2.Heart Vessels.30(3): 362-368, 2014.PubMed
  • 71Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients.Diabetes Metab Res Rev.30(8): 736-741, 2014.PubMed
  • 70Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.AIDS Res Hum Retroviruses.30(4): 363-369, 2014.PubMed
  • 63Moderate-intensity single exercise session does not induce renal damage.J Clin Lab Anal.27(3): 177-180, 2013.PubMed
  • 62A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1.Am J Physiol Renal Physiol.305(12): F1796-1803, 2013.PubMed
  • 60Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy.Diabetes Care.36(5): 1248-1253, 2013.PubMed
  • 58Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.Diabet Med.29(8): e184-190, 2012.PubMed
  • 56Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.Hypertens Res.35(11): 1058-1062, 2012.PubMed
  • 51Potential Benefit of Statin Therapy for Dyslipidemia with Chronic Kidney Disease: Fluvastatin Renal Evaluation Trial (FRET).Internal Medicine.50(12): 1273-1278, 2011.PubMed
  • 50Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.Hypertens Res .34: 935-941, 2011.PubMed
  • 48Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy.Nephrol Dial Transplant.26(7): 2127-2137, 2011.PubMed
  • 45Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis.Nephrol Dial Transplant.26(11): 3465-3473, 2011.PubMed
  • 44Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients.Diabetes Care.34(3): 691-696, 2011.PubMed
  • 41Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.Eur J Clin Invest.40(2): 95-102, 2010.PubMed
  • 40Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients.Diabetes Care.33(6): 1320-1324, 2010.PubMed
  • 39Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.Am J Med Sci.339(2): 157-163, 2010.PubMed
  • 38Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.Kidney Blood Press Res.33(3): 213-220, 2010.PubMed
  • 37Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.Eur J Clin Invest.40(9): 790-796, 2010.PubMed
  • 34Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy.Nephron Clin Pract.112(3): c148-156, 2009.PubMed
  • 33Tubular and glomerular injury in diabetes and the impact of ACE inhibition.Diabetes Care.32(9): 1684-1688, 2009.PubMed
  • 30Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy.Metabolism.58(8): 1185-1190, 2009.PubMed
  • 29Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice.Nephrol Dial Transplant.24(3): 788-800, 2009.PubMed
  • 25Renoprotective effect of telmisartan in patients with chronic kidney disease.Clin Exp Hypertens.30(7): 662-672, 2008.PubMed
  • 24Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.Clin Nephrol.70(5): 385-392, 2008.PubMed
  • 21Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.Diabetologia.50(2): 490-492, 2007.PubMed
  • 20Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.Am J Med Sci.333(6): 321-326, 2007.PubMed
  • 19Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.Am J Hypertens.20(11): 1195-1201, 2007.PubMed
  • 16Cigarette smoking affects urinary liver-type fatty acid-binding protein concentration in patients with early diabetic nephropathy.Diabetes Care.29(7): 1717, 2006.PubMed
  • 15Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.Clin Nephrol.65(1): 1-6, 2006.PubMed
  • 14Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria.Diabetes Metab Res Rev.22(5): 385-389, 2006.PubMed
  • 13Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia.Am J Nephrol.26(3): 276-280, 2006.PubMed
  • 12Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.Am J Nephrol.26(1): 82-86, 2006.PubMed
  • 11Liver-type fatty acid-binding protein attenuates renal injury induced by unilateral ureteral obstruction.Am J Pathol.169(4): 1107-1117, 2006.PubMed
  • 10Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease.Mol Cell Biochem.284(1-2): 175-182, 2006.PubMed
  • 8Clinical Significance of Urinary Liver-Type Fatty acid-binding Protein in Patients With Diabetic Nephropathy.Diabetes Care.28(18): 2038-2039, 2005.PubMed
  • 7Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.TAm J Med Sci.330(4): 161-165, 2005.PubMed
  • 6Effect of Pitavastatin on Urinary Liver-Type Fatty acid-binding Protein Levels in Patients With Early Diabetic Nephropathy.Diabetes Care.28(11): 2728-2732, 2005.PubMed
  • 5Urinary liver-type fatty acid-binding protein: discrimination between IgA nephropathy and thin basement membrane nephropathy.Am J Nephrol.25(5): 447-450, 2005.PubMed
  • 4Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial.J Lab Clin Med.145(3): 125-133, 2005.PubMed
  • 3Urinary excretion of liver fatty acid-binding protein in health-check participants.Clin Exp Nephrol.9(1): 34-39, 2005.PubMed
  • 2Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules.Am J Pathol.165(4): 1243-1255, 2004.PubMed
  • 1Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease.J Lab Clin Med.143(1): 23-30, 2004.PubMed

Category

Download product leaflet

For nonclinical safety evaluation

Urinary L-FABP kits for Rat, Dog, Cat, Monkey and Pig are available for the purpose of monitoring drug nephrotoxicity and drug effectiveness.
Top ▲ Home ▶